Exploratory analyses of meal‐induced heartburn identify distinct clinical phenotypes of gastroesophageal reflux disease
Abstract
Symptoms in symptomatic GERD patients result from esophageal acid exposure and are treated with agents that inhibit gastric acid secretion. We analyzed data from a clinical trial evaluating the effect of ranitidine plus antacid on heartburn severity in GERD patients. After 26 subjects ingested a standard meal and received either placebo or ranitidine‐antacid, heartburn severity (assessed via a visual analog scale), esophageal pH, and gastric pH were measured at 15‐min intervals. Two phenotypes emerged based on heartburn severity patterns: “Persistent Heartburn” (PH), characterized by sustained high severity, and “Non‐persistent Heartburn” (NPH), where severity peaked and then declined. PH subjects had similar gastric acidity but higher overall heartburn severity and lower esophageal acid exposure than NPH subjects. Both phenotypes exhibited esophageal hyperalgesia, with significant heartburn even at esophageal pH above 4.0, and hyperalgesia was more pronounced in PH subjects. These findings suggest that esophageal sensitivity, rather than acid exposure alone, contributes to symptom severity. The differing responses to placebo and ranitidine‐antacid highlight potential mechanisms underlying treatment failure in some GERD patients, emphasizing the need for tailored therapeutic approaches.
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 26 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.